Biolase Archives - Medical Design Sourcing

Biolase appoints chief financial, operating officers

Biolase (Nasdaq:BIOL) announced today that it appointed Jennifer Bright as its new CFO and Steven Sandor as its new COO.

Lake Forest, California-based Biolase — a developer of laser technologies for the dental space — made the promotions of both executives effective immediately. Both will report to Biolase President and CEO John Beaver.

Bright has served as VP of finance since April 2021 and will take on responsibilities as CFO including functional areas of finance, accounting, investor relations and assisting the executive management team in establishing long-range goals, strategies, plans and policies that drive results.

In a news release, Bright said she’s looking forward to collaborating with the teams across the company to drive continued commercial success, engage with the investment community, serve customers and patients.

“Jennifer is a highly valuable financial professional who has demonstrated strong leadership across the bre…

FDA clears Biolase’s laser-assisted microfluidic irrigation device

Biolase (NSDQ:BIOL) and EdgeEndo announced today that the FDA granted 510(k) clearance to the EdgePRO system.

EdgePRO offers endodontists a cleaning and disinfection alternative within root canal procedures as a laser-assisted, microfluidic irrigation device.

Biolase built the EdgePRO platform upon its patented laser technology for debridement, cleaning and disinfection through the removal of infected tissue, biofilms, smear layer and the killing of up to 99% of bacteria commonly found in the root canal. The system combines advanced laser light-sound technology with traditional irrigation solutions, according to a news release.

“We’re very pleased to complete our first OEM project, receive FDA 510(k) clearance, and deliver EdgePro units to EdgeEndo in only 12 months,” Biolase President & CEO John Beaver said in the release. “This achievement is an excellent example of cross-functional teamwork between our two market-leading co…

Biolase names new president and CEO

Biolase (NSDQ:BIOL) today announced that it has appointed John Beaver as president and CEO, effective immediately.

Beaver replaces Todd Norbe, who has served as president and CEO since August 2018. Beaver previously served as the company’s executive VP, chief operating officer and chief financial officer.

“John’s knowledge of the dental industry, combined with his executive management and financial expertise, make him ideal to lead Biolase as we pursue our growth plans,” chairperson of the board Jonathan Lord said in a news release. “Since joining Biolase in 2017, John has spent considerable time in the field with dentists and our sales team ensuring that we are meeting the needs of the dental market. It is this hands-on approach that enabled John to develop and lead our Waterlase Exclusive Trial Program, which is off to a great start in 2021. Additionally, he has been heavily involved in our marketing efforts, and most recently la…

Biolase enters into securities purchase agreement for $6.9m

Biolase (NSDQ:BIOL) announced today that it entered into a securities purchase agreement expected to produce gross proceeds of approximately $6.9 million.

The purchase agreement with certain accredited institutional investors includes a registered direct offering and concurrent private placement with 10.8 million shares of Biolase’s common stock and warrants o purchase 10.8 million shares of the common stock. The combined price for one share and one warrant is set at 64¢.

Until 20 days following the closing of the offering, Biolase will not issue or enter into an agreement to issue any shares of common stock or equivalents, pursuant to the terms of the agreement. Exercise prices on warrants and warrant shares will be subject to adjustment in the event of any stock dividends, splits or other transactions.

Maxim Group, The Benchmark Company and Colliers Securities acted as the placement agents on a “reasonable best efforts” basis in conne…